BioXcel Therapeutics, Inc. (BTAI) Financials
BTAI Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 100.4 million | 141.1 million |
2023-06-30 | 140.1 million | 134.2 million |
2023-03-31 | 180.1 million | 127.1 million |
2022-12-31 | 205.9 million | 129.1 million |
BTAI Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -37.6 million | 4.0 million |
2023-06-30 | -38.2 million | 6.1 million |
2023-03-31 | -52.4 million | 4.9 million |
2022-12-31 | -38.6 million | 4.5 million |
BTAI Net Income
No data available :(
BTAI Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 90.0 million | - | 529000 |
2023-06-30 | 127.5 million | 96.8 million | 949000 |
2023-03-31 | 165.5 million | 95.1 million | 1.0 million |
2022-12-31 | 193.7 million | 93.1 million | 1.1 million |
BTAI Shares Outstanding
BTAI Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | - | 19.6 million | 21.4 million | 3.0 million |
2023-06-30 | 20000 | 27.0 million | 21.1 million | 4.8 million |
2023-03-31 | 20000 | 27.8 million | 23.6 million | - |
2022-12-31 | - | 32.5 million | 20.7 million | 31.0 million |
BTAI Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 341000 | 512000 |
2023-06-30 | 457000 | 26000 |
2023-03-31 | 206000 | 9000 |
2022-12-31 | 238000 | 9000 |
BTAI
Price: $2.63
52 week price:
Earnings Per Share: -6.15 USD
P/E Ratio: -0.51
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 510800
Market Capitalization: 80.4 million